Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-7828 · 1 trial · 1 indication
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Cmax of ABBV-7828
Beta of ABBV-7828
AUCt of ABBV-7878
AUCinf of ABBV-7878
| Arm | Type | Description |
|---|---|---|
| Part 1: ABBV-7828 | EXPERIMENTAL | Participants will receive single doses of ABBV-7828. |
| Part 1: Placebo | PLACEBO_COMPARATOR | Participants will receive single doses of placebo. |
| Part 2: ABBV-7828 Sequence 1 | EXPERIMENTAL | Participants will receive ABBV-7828 while in fasting in Period 1 followed by ABBV-7828 after high fat/high calorie meal in Period 2. |
| Part 2: ABBV-7828 Sequence 2 | EXPERIMENTAL | Participants will receive ABBV-7828 after a high-fat/high calorie meal in Period 1 followed by ABBV-7828 in fasting conditions in Period 2. |
| Name | Type | Description |
|---|---|---|
| ABBV-7828 | DRUG | Oral administration |
| Placebo for ABBV-7828 | DRUG | Oral administration |
Inclusion Criteria: * Individuals between 18 to 65 years of age at the time of screening. * BMI is \<= 18.0 to \>= 32.0 kg/m2. * A condition of general good health, based upon the results of a medical history, physical evaluations, vital signs, laboratory profile and a 12-lead ECG. Exclusion Crite...
ABBV-7828 is an investigational small molecule drug being developed by AbbVie Inc. It is in Phase 1 clinical development, and its intended therapeutic indication has not been disclosed. The compound is being studied first in healthy adult volunteers rather than in patients with a specific disease.
ABBV-7828 is made by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor developing the compound, and the Phase 1 study of ABBV-7828 is being conducted in the United States.
ABBV-7828 is in Phase 1 clinical development. It is an investigational agent and is not approved for any use. Its first clinical study is a single ascending dose and food effect trial in healthy adults, which is currently recruiting participants.
ABBV-7828 is being studied in one Phase 1 trial, NCT07856706, titled a single ascending dose and food effect study of ABBV-7828 in healthy adults. The trial is recruiting, is placebo-controlled and double-blind, and plans to enroll about 60 participants aged 18 years and older in the United States.
The ABBV-7828 Phase 1 trial, NCT07856706, is a randomized, double-blind, placebo-controlled single ascending dose and food effect study in healthy adult volunteers. It plans to enroll approximately 60 participants of any sex, aged 18 years and older, and is currently recruiting in the United States.